Validation of the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4, a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs

2014 ◽  
Vol 25 (2) ◽  
pp. 77-e25 ◽  
Author(s):  
Thierry Olivry ◽  
Manolis Saridomichelakis ◽  
Tim Nuttall ◽  
Emmanuel Bensignor ◽  
Craig E. Griffin ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Severity Index ◽  
Skin Lesions ◽  
Severity Scale ◽  
Canine Atopic Dermatitis

The evaluation of Canine Atopic Dermatitis Extent and Severity Index (CADESI) test in dogs with Atopic Dermatitis (AD) treated with cyclosporine or prednisone

2010 ◽  
Vol 13 (4) ◽  
pp. 681-688 ◽  
Author(s):  
I. Taszkun
Keyword(s):  
Atopic Dermatitis ◽  
Severity Index ◽  
Skin Lesions ◽  
Clinical State ◽  
Point Scale ◽  
Canine Atopic Dermatitis ◽  
Group I ◽  
Oral Preparation ◽  
Sandimmun Neoral ◽  
Anti Inflammatory

The evaluation of Canine Atopic Dermatitis Extent and Severity Index (CADESI) test in dogs with Atopic Dermatitis (AD) treated with cyclosporine or prednisone The purpose of this study was to assess the clinical state of dogs with atopic dermatitis (AD) by use of CADESI test in own modification during the first visit in the Dermatology Consult Room as well as during the treatment. The study was performed in two groups (I-E and II-C) of 20 dogs in each group. In dogs which were qualified to the I-E group, as antiallergic, anti-inflammatory and antipruritic treatment, prednisone (oral preparation Encorton - Polfa Pabianice) at dose 0.5 mg/kg b.w./day was administered, while in dogs qualified to the II-C group - cyclosporine (oral preparation Sandimmun Neoral - Novartis Pharma) at a dose of 5 mg/kg b.w./day; the treatment was continued for 6 weeks in both groups. During the study, skin lesions were assessed in 15 specified body areas using 4 parameters and 5-point scale. In group I-E and II-C the amount of received points in CADESI test was decreased by 82.26% and by 83% respectively, after the treatment. Statistical analyses of the results obtained revealed no statistically significant (P=0.05) differences between means of I-E and II-C groups in consecutive examinations, which indicates comparable clinical efficacy of both drugs. Statistically significant differences (P=0.05) of the parameters assessed were found after secondary dermatoses treatment, and after every two weeks of antipruritic and anti-inflammatory treatment.

scholarly journals Prospective, Comparative Clinical Pilot Study of Cold Atmospheric Plasma Device in the Treatment of Atopic Dermatitis

2021 ◽  
Author(s):  
Young Jae Kim ◽  
Dong Jun Lim ◽  
Mi Young Lee ◽  
Woo Jin Lee ◽  
Sung Eun Chang ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Pilot Study ◽  
Severity Index ◽  
Skin Lesions ◽  
Treated Group ◽  
Atmospheric Plasma ◽  
Clinical Severity ◽  
Control Treatment ◽  
Cold Atmospheric Plasma ◽  
Plasma Device

Abstract Introduction: Cold atmospheric plasma generates free radicals through the ionization of air at room temperature. Its effect and safety profile in patients with atopic dermatitis have not been evaluated prospectively.Objective: We aimed to investigate the effect and safety of cold atmospheric plasma in patients with atopic dermatitis with a prospective pilot study.Methods: Cold atmospheric plasma treatment or sham control treatment were applied respectively in randomly assigned and symmetric skin lesions. Three treatment sessions were performed at weeks 0, 1, and 2. Clinical severity indices were assessed at weeks 0, 1, 2, and 4 after treatment. Additionally, the microbial characteristics of the lesions before and after treatments were analyzed.Results: We included 22 patients with mild to moderate atopic dermatitis presented with symmetric lesions. We found that cold atmospheric plasma can alleviate the clinical severity of atopic dermatitis. Modified atopic dermatitis antecubital severity and eczema area and severity index score were significantly decreased in the treated group. Furthermore, scoring of atopic dermatitis score and pruritic visual analog scales significantly improved. In microbiome analysis revealed significantly reduced proportion of Staphylococcus aureus in the treated group.Conclusion: Cold atmospheric plasma can significantly improve mild and moderate atopic dermatitis without safety issues.

Clinical efficacy of neural therapy for the treatment of atopic dermatitis in dogs

2008 ◽  
Vol 56 (4) ◽  
pp. 459-469 ◽  
Author(s):  
Adriana Bravo-Monsalvo ◽  
Juan Vázquez-Chagoyán ◽  
Lilia Gutiérrez ◽  
Héctor Sumano
Keyword(s):  
Atopic Dermatitis ◽  
Clinical Efficacy ◽  
Severity Index ◽  
Control Group ◽  
Matched Pairs ◽  
Neural Therapy ◽  
Canine Atopic Dermatitis ◽  
Dermatological Condition ◽  
Before And After ◽  
History Of

The aim of this trial was to assess the clinical efficacy of neural therapy (NT) when treating canine atopic dermatitis. Eighteen dogs (no control group), with at least a 12-month history of having nonseasonal atopic dermatitis, were included. No medication with either glucocorticoids or cyclosporin was allowed during the trial. One set of NT was given by injecting an intravenous dose of 0.1 mg/kg of a 0.7% procaine solution, followed by 10 to 25 intradermal injections of the same solution in a volume of 0.1–0.3 mL per site. Dogs were given 6–13 sets of NT during the therapy. The dermatological condition of each patient was evaluated before and after the treatment using two scales: the pruritus visual analogue scale (PVAS) and the canine atopic dermatitis extent and severity index (CADESI). The reduction of pruritus was statistically significant using a Wilcoxon matched-pairs signed-ranks test (P < 0.001). No adverse side effects were observed. NT seems to be an effective alternative to control signs related to canine atopic dermatitis.

Fluoxetine (SSRI) treatment of canine atopic dermatitis: a randomized, double-blind, placebo-controlled, crossover trial

2014 ◽  
Vol 17 (2) ◽  
pp. 371-373 ◽  
Author(s):  
M. Fujimura ◽  
H. Ishimaru ◽  
Y. Nakatsuji
Keyword(s):  
Atopic Dermatitis ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Crossover Trial ◽  
Severity Index ◽  
Base Line ◽  
Double Blind ◽  
Canine Atopic Dermatitis ◽  
Double Blind Placebo ◽  
Significant Difference ◽  
Ssri Treatment

Abstract This study investigated effects of a fluoxetine (selective serotonin reuptake inhibitors; SSRI, 1 mg/kg) on pruritus in canine atopic dermatitis (CAD). After 4-weeks of base-line observation, 8 dogs with CAD entered a 2-months randomized, double-blind, placebo-controlled, crossover trial comparing fluoxetine with placebo. Clinical efficacy was evaluated using a Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) and Pruritus Visual Analog Scale (PVAS). Six dogs completed the study [two out of eight dogs (both of them were Shiba Inu) dropped out from the study due to a depression]. CADESI-03 and PVAS between fluoxetine and placebo showed no significant difference statistically (P>0.05 and P>0.05 respectively). Fluoxetine showed no efficacy on pruritus in CAD. Further researches are needed for the treatment on pruritus of CAD

scholarly journals Spot-On Skin Lipid Complex as an Adjunct Therapy in Dogs with Atopic Dermatitis: An Open Pilot Study

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Masato Fujimura ◽  
Yoshinobu Nakatsuji ◽  
Subaru Fujiwara ◽  
Christophe Rème ◽  
Hugues Gatto
Keyword(s):  
Atopic Dermatitis ◽  
Marked Reduction ◽  
Severity Index ◽  
Lipid Complex ◽  
Adjunct Therapy ◽  
Skin Lipid ◽  
Canine Atopic Dermatitis ◽  
The Third ◽  
Clinical Benefits ◽  
Open Pilot

The purpose of this paper was to evaluate the efficacy of topical skin lipid complex (SLC) in canine atopic dermatitis (AD). Eight dogs with chronic AD and no improvement of main therapy in symptoms, erythema, lichenification, excoriation, and alopecia in the previous month were treated with SLC topically as adjunct therapy at lesion sites twice weekly for 12 weeks. A statistically significant reduction (26.0%, ) in the third version of the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) modification from baseline was recorded 6 weeks after treatment, with marked reduction in the erythema subscore (36.2%, ). A significant reduction in excoriation and alopecia subscores was observed 6 weeks after treatment (39.9%, and 19.9%, , resp.). However, the lichenification subscore was not reduced significantly at 6 or 12 weeks. These findings suggest that topical SLC may have therapeutic and clinical benefits in dogs with AD.

scholarly journals Canine atopic dermatitis in the Middle East: clinical signs, signalment and common allergens

2012 ◽  
Vol 57 (No. 8) ◽  
pp. 410-419 ◽  
Author(s):  
G. Zur ◽  
I. Skorinsky ◽  
T. Bdolah-Abram
Keyword(s):  
Atopic Dermatitis ◽  
Middle Eastern ◽  
Disease Onset ◽  
Clinical Signs ◽  
Onset Time ◽  
Skin Lesions ◽  
The Body ◽  
German Shepherd ◽  
Canine Atopic Dermatitis ◽  
German Shepherd Dog

&nbsp; The aim of the study was to examine for the first time the various aspects of canine atopic dermatitis (CAD) presenting in a Middle Eastern country. Medical records of 164 dogs diagnosed with CAD were evaluated. Associations between signalment, lifestyle, clinical signs and allergens were evaluated statistically. Labrador Retriever, German Shepherd dog, Boxer, French Bulldog, Golden Retriever and Shar-Pei breeds were presented more frequently than the regular hospital population (P &lt; 0.0001), and had an earlier disease onset time (P &lt; 0.01). In 22 dogs (13%) signs of CAD were noticed at less than six months of age. Most dogs (75%) lived indoors. Most dogs (83%) had lesions on the ventral part of the body and 68% had foot lesions. After excluding flea allergy dermatitis by implementing strict flea control, 60% of the dogs presented with dorsal distribution of skin lesions. Dogs with ventral lesions were younger when clinical signs first appeared (P &lt; 0.05). Most of the dogs were allergic to dust and/or dust mites (75.6%), with weeds and trees as the next most common allergens. CAD is similar worldwide, but geographic differences may be attributable to genetic pools and allergen loading. This study also shows that early onset of clinical signs, especially in breeds predisposed to CAD and with a dorsal distribution of skin lesions, should not rule out the diagnosis of CAD. &nbsp;

The Influence of Topical Unsaturated Fatty Acids and Essential Oils on Normal and Atopic Dogs

2011 ◽  
Vol 47 (4) ◽  
pp. 236-240 ◽  
Author(s):  
Sandra Tretter ◽  
Ralf S. Mueller
Keyword(s):  
Fatty Acids ◽  
Atopic Dermatitis ◽  
Essential Oils ◽  
Unsaturated Fatty Acids ◽  
Severity Index ◽  
Transepidermal Water Loss ◽  
Closed Chamber ◽  
Canine Atopic Dermatitis ◽  
Significant Difference ◽  
Before And After

Seven dogs with atopic dermatitis and six normal dogs were treated with a spot-on product containing essential oils and unsaturated fatty acids q 7 days for 8 wk. Seven additional atopic dogs received a daily spray containing similar ingredients to the spot-on. In all dogs, transepidermal water loss (TEWL) was measured before and after treatment using a closed chamber device. In atopic dogs, a validated lesion score (canine atopic dermatitis extent and severity index, CADESI) was determined and pruritus was assessed with a visual analog scale before and after treatment. The mean CADESI scores in atopic dogs decreased with the spot-on (P=0.0043) and with the spray (P=0.0366). Similarly, the pruritus scores decreased with the spot-on (P=0.266) and with the spray (P=0.0177). There was a significant difference between the TEWL values of healthy and atopic dogs on the abdomen (P=0.0181) and back (P=0.0123). TEWL decreased significantly on the back after treatment with the spray (P=0.016), but not on the abdomen (P=0.078). Adverse effects were not observed. The results of this pilot study indicate that topical fatty acids and essential oils are a useful treatment option for canine atopic dermatitis.

scholarly journals Early Activation of Th2/Th22 Inflammatory and Pruritogenic Pathways in Acute Canine Atopic Dermatitis Skin Lesions

2016 ◽  
Vol 136 (10) ◽  
pp. 1961-1969 ◽  
Author(s):  
Thierry Olivry ◽  
David Mayhew ◽  
Judy S. Paps ◽  
Keith E. Linder ◽  
Carlos Peredo ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Skin Lesions ◽  
Canine Atopic Dermatitis ◽  
Early Activation

scholarly journals Canine atopic dermatitis (atopy)

2018 ◽  
Vol 49 (1) ◽  
pp. 16
Author(s):  
M. N. SARIDOMICHELAKIS (Μ. Ν. ΣΑΡΙΔΟΜΙΧΕΛΑΚΗΣ) ◽  
A. F. KOUTINAS (Α.Φ. ΚΟΥΤΙΝΑΣ)
Keyword(s):  
Atopic Dermatitis ◽  
Skin Diseases ◽  
Essential Fatty Acids ◽  
Clinical Signs ◽  
Skin Lesions ◽  
High Rate ◽  
Intradermal Test ◽  
Secondary Complications ◽  
Canine Atopic Dermatitis ◽  
Pharmacologically Active

Canine atopic dermatitis is a common clinical entity, characterized by pruritus due to sensitization against common enviromental allergens. It has been proven that there is strong breed predisposition. Genetically programmed dogs overproduct reaginic antibodies (IgE and/or IgGd) after their exposure to airborne allergens (dust mites, epithelia, pollens and molds) which consequently fix themselves to the mast cells of the skin. After reexposure to the same allergens these cells degranulate, with subsequent release of many pharmacologically active substances (histamine, leucotrienes, Prostaglandines etc). However, this is a rather simplistic explanation; the true pathogenesis of atopy is more complicated and still not well understood. Clinical signs first appear between 6 months and 3 years of age. Pruritus, the mainstay of atopy, can be seasonal or perennial. Skin lesions, appearing in later, are attributed to pruritus and/or to secondary complications (staphylococcal pyoderma, seborrhea, dry skin, Malassezia dermatitis). The diagnosis, based on history and clinical findings, necessitates exclusion of other pruritic skin diseases and identification of the offending allergens by using the intradermal test and/or serology (ELISA, RAST). The latter method is diagnostically inferior to intradermal skin test due to the high rate of false positive reactions. Therapeutic options include avoidance of the allergens responsible for sensitization, systemic therapy with glucocorticoids, antihistamines and essential fatty acids in various combinations, topical antipruritic therapy, hyposensitization which is the best therapeutical modality for the perennial form of the disease and management of secondary complications as well as of other concurrent allergic skin diseases, such as food and flea allergy.

Sign in / Sign up

Export Citation Format

Share Document